Correction: Evaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancer M. BraunM. HamannE. Huber Correction 19 June 2025
Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival of metastatic breast cancer patients receiving CDK 4/6i, PI3Ki, and/or mTORi Jeffrey FranksAndres AzueroGabrielle Rocque Research Open access 18 June 2025
Mammographic calcifications association with risk of advanced breast cancer Karla KerlikowskeLinn AbrahamDiana L. Miglioretti Research Open access 17 June 2025
Promoting resilience in stress management (PRISM) for patients with early stage breast cancer: a pilot feasibility study Gabrielle B RocqueEtzael Ortiz OlguinAbby R. Rosenberg Research Open access 16 June 2025
Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysis Vitor Teixeira LiuttiDavid Laios do ValeDaniel Vilarim Araújo Review 13 June 2025
Local treatment of ipsilateral breast cancer recurrence: a sensitive decision-making process Jean-Michel Hannoun-LeviVratislav Strnadthe BCWG of the GEC-ESTRO Letter to the Editor 12 June 2025
PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis Eunah ShinYoon Jin ChaJa Seung Koo Research 11 June 2025
Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial Axel Stenmark TullbergViktoria ThurfjellCarina Strell Research Open access 09 June 2025
Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers Sneha PhadkeKathy D. MillerKari B. Wisinski Research Open access 05 June 2025
Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer Sophie R. UleneShikun WangMelissa K. Accordino Research 04 June 2025
A mixed-methods study characterizing experiences of medical oncologists’ use of gonadotropin-releasing hormone agonists for treatment of breast cancer Kimberley T. LeeBihe HuDawn L. Hershman Research Open access 03 June 2025
Insurer and patient costs for repeat breast surgery after initial lumpectomy for breast cancer Sam E. WingYuki LiuJesse C. Selber Research Open access 03 June 2025
National trends in neoadjuvant systemic therapy utilization in patients with early-stage HER2-positive breast cancer from 2016–2021: The impact of the KATHERINE trial Lauren N. CohenChristine C. RogersChandler S. Cortina Research 03 June 2025
Breast imaging recommendations for young females (age < 40 years) with ≥ 20% lifetime breast cancer risk: practice patterns at a specialized clinic Alexandra WehbeFisher KatlinAlison Laws Research 01 June 2025
Severe hyponatremia with abemaciclib use in the absence of pre-existing renal disease Tae Hoon KimAmanda PodolskiEleonora Teplinsky Brief Report 31 May 2025
Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials Nour Maher MustafaMus’ab Theeb MustafaAreen Shdaifat Review 31 May 2025
Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study Gilbert BaderJulia C. F. QuintanilhaDaniel G. Stover Research Open access 30 May 2025
Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes Arielle J. MedfordMarko VelimirovicAditya Bardia Research Open access 29 May 2025
